Description: Zenosense, Inc. (Zenosense) is focused on commencing the business of developing specialized and non-invasive disease sensory devices. The Company's focus is on products designed to detect methicillin resistant Staphylococcus aureus (MRSA) /Staphylococcus aureus (SA) when present in healthcare environments and to detect the presence of lung cancer in a patient. The Company's product is focused on sampling the air and continuously monitoring the airborne, the volatile organic compounds (VOCs) signatures emitted, by MRSA/SA. The Company's device with a single sensor is focused on performing the entire VOC spectrum scan, as the adaptive processing software enables it to perform various scans, creating multiple virtual sensors from a single sensor. The Company's device is intended to be produced in two forms: a wearable/bed-positioned device and an adapted, fixed device positioned in the room.
Home Page: www.zenosense.com
1185 Avenue of the Americas
New York,
NY
10036
United States
Phone:
646 768 8417
Officers
| Name | Title |
|---|---|
| Mr. Zhongjian Hu | Chief Exec. Officer |
| Mr. Dong Wei | Chief Financial Officer |
| Ms. Ruirui Xu | Exec. Director |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 216.3714 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |